Gordon Sanghera  is the co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005 having acted as a consultant since February 2005 whilst the Company was established. He brings over 15 years' experience in the design, development and global launch of novel point-of-care biosensor devices.

At Abbott Laboratories, Dr Sanghera held both UK and US director-level positions, including Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose biosensor systems for the consumer and medical markets. He has also developed and validated market production processes to meet with the regulatory requirements for USA and Europe.

Gordon has a DPhil in biosensor technology and a degree in Chemistry

 

Oxford Nanopore Technologies Ltd is developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments MinION, PromethION and GridION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalised medicine, crop science and security/defence.